Cargando…

Targeted Therapeutic Approaches in Vulvar Squamous Cell Cancer (VSCC): Case Series and Review of the Literature

Therapeutic options in recurrent or metastasized vulvar squamous cell cancer (VSCC) not amenable to radiotherapy or radical surgery are limited. Evidence for the use of targeted therapies is sparse. All patients with VSCC treated at the Gynecological Cancer Center Hamburg-Eppendorf 2013–2019 were re...

Descripción completa

Detalles Bibliográficos
Autores principales: Woelber, Linn, Mathey, Sabrina, Prieske, Katharina, Kuerti, Sascha, Hillen, Christoph, Burandt, Eike, Coym, Anja, Mueller, Volkmar, Schmalfeldt, Barbara, Jaeger, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cognizant Communication Corporation 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7962928/
https://www.ncbi.nlm.nih.gov/pubmed/33308371
http://dx.doi.org/10.3727/096504020X16076861118243
_version_ 1783665542627852288
author Woelber, Linn
Mathey, Sabrina
Prieske, Katharina
Kuerti, Sascha
Hillen, Christoph
Burandt, Eike
Coym, Anja
Mueller, Volkmar
Schmalfeldt, Barbara
Jaeger, Anna
author_facet Woelber, Linn
Mathey, Sabrina
Prieske, Katharina
Kuerti, Sascha
Hillen, Christoph
Burandt, Eike
Coym, Anja
Mueller, Volkmar
Schmalfeldt, Barbara
Jaeger, Anna
author_sort Woelber, Linn
collection PubMed
description Therapeutic options in recurrent or metastasized vulvar squamous cell cancer (VSCC) not amenable to radiotherapy or radical surgery are limited. Evidence for the use of targeted therapies is sparse. All patients with VSCC treated at the Gynecological Cancer Center Hamburg-Eppendorf 2013–2019 were retrospectively evaluated for targeted therapeutic approaches. Furthermore, a MEDLINE, EMBASE, Web of Science, Scopus, and OVID database search was performed using the terms: “vulvar cancer” AND “targeted therapy,” “erlotinib,” “EGFR,” “bevacizumab,” “VEGF,” “pembrolizumab,” or “immunotherapy.” Twelve of 291 patients (4.1%) with VSCC received at least one targeted therapy at our institution. Previously, one or more platinum-based chemotherapy was applied to all patients [median 3.5 previous lines (range 2–5)]. In the erlotinib subgroup, two of five patients (40%) achieved stable disease (SD), while two patients (2/5, 40%) experienced partial response (PR). Treatment was given as monotherapy in second/third line for a median of 3.4 months (range 2–6 months). Bevacizumab (n = 9) was given as maintenance therapy after platinum-based first-line chemotherapy (9/9); best response was complete response (CR) (n = 2/9 22.2%). Median duration of treatment was 7 months (range 4–13 months) with two patients still under ongoing treatment. Best response in the pembrolizumab (n = 3) subset was SD (n = 1/3 33%). Treatment was given as monotherapy in second/third line for a median of 3.3 months (range 3–4 months). Nine of 12 patients (75%) experienced treatment-related adverse events (TRAEs), most commonly grade 1/2. Rapidly evolving antibody treatments have proven clinical benefit especially in HPV-driven tumor entities; however, clinical investigations in VSCC are still limited. These reported cases provide evidence for the clinical utility and feasibility while ensuring an acceptable safety profile.
format Online
Article
Text
id pubmed-7962928
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cognizant Communication Corporation
record_format MEDLINE/PubMed
spelling pubmed-79629282021-03-27 Targeted Therapeutic Approaches in Vulvar Squamous Cell Cancer (VSCC): Case Series and Review of the Literature Woelber, Linn Mathey, Sabrina Prieske, Katharina Kuerti, Sascha Hillen, Christoph Burandt, Eike Coym, Anja Mueller, Volkmar Schmalfeldt, Barbara Jaeger, Anna Oncol Res Article Therapeutic options in recurrent or metastasized vulvar squamous cell cancer (VSCC) not amenable to radiotherapy or radical surgery are limited. Evidence for the use of targeted therapies is sparse. All patients with VSCC treated at the Gynecological Cancer Center Hamburg-Eppendorf 2013–2019 were retrospectively evaluated for targeted therapeutic approaches. Furthermore, a MEDLINE, EMBASE, Web of Science, Scopus, and OVID database search was performed using the terms: “vulvar cancer” AND “targeted therapy,” “erlotinib,” “EGFR,” “bevacizumab,” “VEGF,” “pembrolizumab,” or “immunotherapy.” Twelve of 291 patients (4.1%) with VSCC received at least one targeted therapy at our institution. Previously, one or more platinum-based chemotherapy was applied to all patients [median 3.5 previous lines (range 2–5)]. In the erlotinib subgroup, two of five patients (40%) achieved stable disease (SD), while two patients (2/5, 40%) experienced partial response (PR). Treatment was given as monotherapy in second/third line for a median of 3.4 months (range 2–6 months). Bevacizumab (n = 9) was given as maintenance therapy after platinum-based first-line chemotherapy (9/9); best response was complete response (CR) (n = 2/9 22.2%). Median duration of treatment was 7 months (range 4–13 months) with two patients still under ongoing treatment. Best response in the pembrolizumab (n = 3) subset was SD (n = 1/3 33%). Treatment was given as monotherapy in second/third line for a median of 3.3 months (range 3–4 months). Nine of 12 patients (75%) experienced treatment-related adverse events (TRAEs), most commonly grade 1/2. Rapidly evolving antibody treatments have proven clinical benefit especially in HPV-driven tumor entities; however, clinical investigations in VSCC are still limited. These reported cases provide evidence for the clinical utility and feasibility while ensuring an acceptable safety profile. Cognizant Communication Corporation 2021-03-16 /pmc/articles/PMC7962928/ /pubmed/33308371 http://dx.doi.org/10.3727/096504020X16076861118243 Text en Copyright © 2021 Cognizant, LLC. http://creativecommons.org/licenses/by-nc-nd/4.0/ This article is licensed under a Creative Commons Attribution-NonCommercial NoDerivatives 4.0 International License.
spellingShingle Article
Woelber, Linn
Mathey, Sabrina
Prieske, Katharina
Kuerti, Sascha
Hillen, Christoph
Burandt, Eike
Coym, Anja
Mueller, Volkmar
Schmalfeldt, Barbara
Jaeger, Anna
Targeted Therapeutic Approaches in Vulvar Squamous Cell Cancer (VSCC): Case Series and Review of the Literature
title Targeted Therapeutic Approaches in Vulvar Squamous Cell Cancer (VSCC): Case Series and Review of the Literature
title_full Targeted Therapeutic Approaches in Vulvar Squamous Cell Cancer (VSCC): Case Series and Review of the Literature
title_fullStr Targeted Therapeutic Approaches in Vulvar Squamous Cell Cancer (VSCC): Case Series and Review of the Literature
title_full_unstemmed Targeted Therapeutic Approaches in Vulvar Squamous Cell Cancer (VSCC): Case Series and Review of the Literature
title_short Targeted Therapeutic Approaches in Vulvar Squamous Cell Cancer (VSCC): Case Series and Review of the Literature
title_sort targeted therapeutic approaches in vulvar squamous cell cancer (vscc): case series and review of the literature
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7962928/
https://www.ncbi.nlm.nih.gov/pubmed/33308371
http://dx.doi.org/10.3727/096504020X16076861118243
work_keys_str_mv AT woelberlinn targetedtherapeuticapproachesinvulvarsquamouscellcancervscccaseseriesandreviewoftheliterature
AT matheysabrina targetedtherapeuticapproachesinvulvarsquamouscellcancervscccaseseriesandreviewoftheliterature
AT prieskekatharina targetedtherapeuticapproachesinvulvarsquamouscellcancervscccaseseriesandreviewoftheliterature
AT kuertisascha targetedtherapeuticapproachesinvulvarsquamouscellcancervscccaseseriesandreviewoftheliterature
AT hillenchristoph targetedtherapeuticapproachesinvulvarsquamouscellcancervscccaseseriesandreviewoftheliterature
AT burandteike targetedtherapeuticapproachesinvulvarsquamouscellcancervscccaseseriesandreviewoftheliterature
AT coymanja targetedtherapeuticapproachesinvulvarsquamouscellcancervscccaseseriesandreviewoftheliterature
AT muellervolkmar targetedtherapeuticapproachesinvulvarsquamouscellcancervscccaseseriesandreviewoftheliterature
AT schmalfeldtbarbara targetedtherapeuticapproachesinvulvarsquamouscellcancervscccaseseriesandreviewoftheliterature
AT jaegeranna targetedtherapeuticapproachesinvulvarsquamouscellcancervscccaseseriesandreviewoftheliterature